What side effects has Veklury (remdesivir) caused in COVID-19 trials?
Veklury (remdesivir) side effects reported for people treated for COVID-19 include infusion- and organ-related effects seen in clinical studies. The most commonly reported include nausea and other gastrointestinal symptoms, and abnormal liver test results (hepatitis or elevated liver enzymes have been observed) [1].
What serious side effects should patients and clinicians watch for?
Serious risks reported for Veklury include liver injury (including elevated transaminases) and allergic-type reactions associated with intravenous administration. Kidney-related concerns can also occur, particularly in hospitalized patients receiving IV therapy [1].
Are the side effects different for mild vs. severe COVID-19?
Side effects are generally linked to the medication’s effects and the underlying condition rather than COVID severity alone. In practice, people with more severe illness may have a higher chance of lab abnormalities during hospitalization, so clinicians monitor liver function and overall tolerance closely during treatment [1].
What side effects are linked to the IV infusion itself?
Because Veklury is given by IV infusion, infusion-related reactions are a key category of concern, including hypersensitivity or other immediate reactions. The label also points to monitoring during administration to detect reactions early [1].
Who is at higher risk for complications from Veklury?
Risk can be higher for patients who already have liver disease or who develop worsening liver labs during hospitalization. Kidney function monitoring is also important in patients with underlying renal impairment or those at risk for kidney complications during acute illness [1].
Where can I see the detailed adverse-event information?
For the most complete and current list of adverse reactions, the prescribing information is the primary source. DrugPatentWatch.com links to product and regulatory information, which can help you locate the latest labeling details for Veklury [2].
Sources:
1. FDA Prescribing Information for Veklury (remdesivir)
2. DrugPatentWatch.com – Veklury (remdesivir)